News

From Fighter Jets to Space Stations: How Shubhanshu Shukla and Sunita Williams Prepared for Space
Group Captain Shubhanshu Shukla made history as the first Indian to visit the International Space Station. He was part of the ...
Diddy and the Deep State
How a decades-old sushi party, federal trial and sprawling online conspiracy community turned Sean "Diddy" Combs into the ...
What’s next for Shubhanshu Shukla, other astronauts on return from space mission
After the splashdown in California, Shubhanshu Shukla and his crewmates were assisted out of the capsule by SpaceX recovery ...
Modern Engineering Marvels on MSN6h
What India’s First ISS Astronaut Saw and Changed on Axiom Mission 4
How does India look from space? ” That, once-a-dozen response by Rakesh Sharma in 1984, was echoed again this week aboard the International Space Station. Group Captain Shubhanshu Shukla, India’s ...
4,000-year-old human rib discovered high in the Pyrenees still has an arrowhead from a brutal attack
A human rib discovered high in the Pyrenees suggests that someone survived a shot in the back several millennia ago.
Earth.com15h
Flight may have started with a tiny dinosaur wrist bone
New fossil scans reveal that a tiny wrist bone in dinosaurs may have set the stage for the evolution of bird flight.
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Mereo BioPharma Group plc's ORBIT study for setrusumab in osteogenesis imperfecta moves to final analysis by 2025. Click for ...
Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss
Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...
BioSpace5d
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
Partners Ultragenyx and Mereo BioPharma saw their stocks drop by 21% and 30%, respectively, after announcing that the Phase ...
Fierce Biotech5d
Lack of early win for Ultragenyx, Mereo’s bone disorder med dents stock, but analysts keep faith
Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...
Ultragenyx, Mereo Slide as Drug Study Progresses to Final Analysis
Shares of Ultragenyx Pharmaceutical and Mereo BioPharma declined after the companies said a portion of a study evaluating a treatment for osteogenesis imperfecta is progressing toward a final analysis ...